Generic Drugmakers Key to Boosting Medicine Access in Africa, Report Finds

Africa’s healthcare landscape is shifting, with a rising tide of non-communicable diseases like diabetes and cancer alongside persistent infectious disease burdens. This evolving health profile is placing immense pressure on already fragile pharmaceutical supply chains, making consistent access to vital medications a significant concern.

For instance, the report by the Access to Medicine Foundation estimates that only about half of individuals with type 1 diabetes in Africa have reliable access to insulin. Similarly, fragmented procurement systems hinder the steady availability of cardiovascular drugs in several nations. This situation is projected to intensify as non-communicable diseases are predicted to become the leading cause of death in sub-Saharan Africa within the next five years.

Despite these hurdles, the African pharmaceutical sector is poised for growth. Initiatives aimed at boosting local drug production, standardizing regulations, enhancing regional trade, and attracting investment could significantly ease the cross-border supply of medicines. Generic drug manufacturers, responsible for a substantial volume of global medicine supply, are central to these efforts, offering affordable treatments to millions.

The report specifically analyzed the strategies of eight companies, including Aspen Pharmacare, Cipla, and Viatris. It found these firms are actively working to strengthen their supply chains, diversify their treatment portfolios to include chronic disease medications, and forge partnerships to increase local manufacturing capabilities.

However, the report cautions that manufacturers cannot tackle Africa’s access-to-medicine issues alone. Challenges such as uncertain demand, fragmented markets, and the complexities of pharmaceutical production make significant investment difficult. Differences in regulatory requirements and poorly coordinated procurement systems further complicate planning for regional manufacturers.

To overcome these barriers, the report suggests exploring avenues like technology-transfer agreements and WHO prequalification. It also notes a growing trend of partnerships focused on building local manufacturing capacity through shared expertise and production arrangements, moving beyond simple distribution deals.

Ultimately, creating a more predictable and integrated pharmaceutical market requires a collective effort. Governments, regulators, procurement agencies, and global health organizations must collaborate with manufacturers to improve demand forecasting, standardize regulations, and direct investment towards critical local production capabilities. Such coordinated action could lead to more reliable and affordable medicine supplies for patients across Africa as their health needs continue to change.

This report was compiled by the Access to Medicine Foundation, examining the role of eight pharmaceutical manufacturers in Africa. https://observer.ug/news/report-highlights-role-of-generic-drugmakers-in-expanding-medicine-access-in-africa